Androgen receptor expression in the urinary bladder urothelial carcinoma and its relation to known prognostic factors

Abstract

Objective: The current study was carried out to assess the prognostic value of androgen receptor expression in urothelial carcinoma of the bladder and correlate it to the disease outcome. Methods: Histologically confirmed cases of bladder urothelial carcinoma were studied. Clinical, pathological, and radiological data were collected. Paraffin embedded tissue sections were submitted for hematoxylin and eosin staining, as well as immunohistochemical staining for androgen receptor in tumor cells. Results: Nuclear androgen receptor expression was positive in 75% of the studied histopathological specimens. Additionally, a significant positive association between androgen receptor expression and tumor grade, muscle invasion & tumor size were noticed. Conclusions: There is a significant association between large tumor size, high grade, deep invasion, and expression of Androgen receptor in urothelial bladder carcinoma. Antiandrogen could be an effective chemo preventive or therapeutic approach in treatment of urothelial bladder carcinoma.

Keywords

Androgen receptor / Urothelial carcinoma / Pathology / Prognostic factor

Conflicts of Interest Disclosure

The authors declare no conflict of interest.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424. PMid:30207593. https://doi.org/10.3322/caac. 21492

[2] Ibrahim AS, Khaled HM, Mikhail NN, et al. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014; 2014: 1-18. PMid:25328522. https://doi.org/10.1155/2014/437971

[3] Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005; 66(6Suppl 1): 4-34. PMid:16399414. https://doi.org/10.1016/j.urol ogy. 2005. 07.062

[4] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2): 71-96. PMid:18287387. https://doi.org/ 10.3322/CA. 2007.0010

[5] Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015; 15(1): 25-41. PMid:25533674. https://doi.org/10. 103 8/nrc3817

[6] Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol. 2001; 40(2): 144-50. PMid:11528191. https://doi.org/10.1159/000049765

[7] Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528): 558-62. PMid:25428503. https://doi.org/10.1038/nature13904

[8] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10-29. PMid:22237781. https://doi. or g/10.3322/caac. 20138

[9] McCahy PJ, Harris CA, Neal DE. The accuracy of recording of occupational history in patients with bladder cancer. Br J Urol. 1997; 79(1): 91-3. PMid:9043504. https://doi.org/10.1046/j. 14 64-410X.1997.30119.x

[10] Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007; 99(7): 558-68. PMid:17406000. https: //doi.org/10.1093/jnci/djk113

[11] Shiota M, Yokomizo A, Takeuchi A, et al. Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. Oncotarget. 2015; 6(16): 14710-9. PMid:25900243. https://doi.org/10.18632/oncotarget. 38 17

[12] Thomas JC, Oottamasathien S, Makari JH, et al. Temporal-spatial protein expression in bladder tissue derived from embryonic stem

[13] cells. J Urol. 2008; 180(4 Suppl): 1784-9. PMid:18721943. https: //doi.org/10.1016/j.juro.2008.03.098

[14] Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83(6): 835-9. https://doi.org/10.1016/0092-8674(95)90199-X

[15] Eder IE, Culig Z, Putz T, et al. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol. 2001; 40(3): 241-51. PMid:11684838. https://doi.org/10.1159/00 0049782

[16] Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007; 28(7): 778-808. PMid:17940184. https://doi.org/10.1210/er.2007-0019

[17] Chang C, Lee SO, Yeh S, et al. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014; 33(25): 3225-34. PMid:23873027. https://doi.org/10.1038/onc.2013.274

[18] Amin MB, Edge SB, Greene FL.AJCC cancer staging manual. New York, NY: Springer; 2017.

[19] Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005; 13(2): 143-53. PMid:15864376. https://doi.org/10.1177/10 6689690501300203

[20] Yao JL, Ryan CK, Francis CW, et al. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009; 27(4): 430-4. PMid:19219655. https://doi.org/10. 108 0/07357900802527247

[21] Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013; 63(2): 234-41. PMid:22877502. https://doi.org/10.1016/j.eururo. 2012. 07.033

[22] Charlton ME, Adamo MP, Sun L, et al. Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010. Cancer. 2014; 120 Suppl 23: 3815-25. PMid:25412393. https://doi.org/10.1002/cncr. 2 9047

[23] Shiota M, Takeuchi A, Yokomizo A, et al. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. J Urol. 2012; 188(1): 276-86. PMid:22608749. https://doi.org/10.1016/j.juro.2012.02.2554

[24] Zhuang YH, Blauer M, Tammela T, et al. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology. 1997; 30(6): 556-62. PMid:9205860. https://doi.org/10. 104 6/j.1365-2559.1997.5610801.x

[25] Ide H, Miyamoto H. Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor. Dis Markers. 2015; 2015: 840640. PMid:26770009. https://doi.org/10.1155/2015/840640

[26] Kashiwagi E, Fujita K, Yamaguchi S, et al. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. Cancer Biol Ther. 2016; 17(11): 1188-96. PMid:27635763. https://doi.org/10.1080/153840 47.2016.1235667

[27] Mashhadi R, Pourmand G, Kosari F, et al. Role of steroid hormone receptors in formation and progression of bladder carcinoma: a casecontrol study. Urol J. 2014; 11(6): 1968-73.

[28] Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004; 64(2): 383-8. PMid:15302512. https: //doi.org/10.1016/j.urology.2004.03.025

[29] Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol. 2011; 29(1): 43-51. PMid:19372057. https://doi.org/10.1016/j.urolon c. 2009.01.033

[30] Nam JK, Park SW, Lee SD, et al. Prognostic value of sex-hormone receptor expression in non-muscle-invasive bladder cancer. Yonsei Med J. 2014; 55(5): 1214-21. PMid:25048477. https://doi.org/ 10.3349/ymj.2014.55.5.1214

[31] Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012; 109(11): 1716-26. PMid:22221549.https://doi.org/10.1111/j.1464-410X. 20 11.10706.x

[32] Williams EM, Higgins JP, Sangoi AR, et al. Androgen receptor immunohistochemistry in genitourinary neoplasms. Int Urol Nephrol. 2015; 47(1): 81-5. PMid:25218615. https://doi.org/10.1007/ s11255-014-0834-7

[33] Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog. 2011; 50(12): 931-44. PMid:21400613. https: //doi.org/10.1002/mc. 20758

[34] Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011; 108(1): 24-30. PMid:21070579. https: //doi.org/10.1111/j.1464-410X.2010.09834.x